http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109265488-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F17-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109265488-B |
| titleOfInvention | Iridium anticancer complex containing phosphinimine bidentate chelating ligand and preparation method and application thereof |
| abstract | The invention discloses an organic metal iridium anticancer complex containing phosphinimine bidentate chelate ligand, (ii) a The prepared complex has an inhibiting effect on the growth of adenocarcinoma human alveolar basal epithelial cells (A549), and the in vitro anticancer activity of the complex is proved to be good. The iridium complex can be subjected to substituent modification at multiple positions, has good anticancer activity, and is a new class of potential anticancer drugs. |
| priorityDate | 2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.